Looks like two abstracts from SITC coming up in November. I could have missed a few. Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy Lawrence Thomas1, Laura Vitale2, Thomas O'Neill2, Jenifer Widger2, Andrea Crocker2, Li-Zhen He2, Jeffrey Weidlick2, Karuna Sundarapandiyan2, James Storey1, Eric Forsberg1, Catherine Pilsmaker1, Lauren Gergel1, Elizabeth Do1, Joel Goldstein2, Henry Marsh1, Tibor Keler2 1Celldex Therapeutics, Needham, MA, USA 2Celldex Therapeutics, Hampton, NJ, USA
Glembatumumab Vedotin (GV), an Anti-gpNMB Antibody-Drug Conjugate (ADC), in Combination with Varlilumab (V), an Anti-CD27 Antibody, in Advanced Melanoma Omid Hamid1, Anna C. Pavlick2, C. Lance Cowey3, Lowell Hart4, Douglas B. Johnson5, Jose Lutzky6, Aaron Alizadeh7, David Spigel8, Neal Rothschild9, April Salama10, Robert Weber11, Jason J. Luke12, Ying Wang13, Michael Yellin13, Yi He13, Rebecca G. Bagley13, Patrick Ott14 1The Angeles Clinic and Research Institute, Los Angeles, CA, USA 2New York University School of Medicine, New York, NY, USA 3Baylor University Medical Center, Dallas, TX, USA 4Florida Cancer Specialists, Fort Myers, FL, USA 5Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN, USA 6Mount Sinai Comprehensive Cancer Center, Miami Beach, FL, USA 7Northside Hospital, Atlanta, GA, USA 8Tennessee Oncology, PLLC, Nashville, TN, USA 9Florida Cancer Specialists, West Palm Beach, FL, USA 10Duke University, Durham, NC, USA 11St. Mary's Medical Center, San Francisco, CA, USA 12University of Chicago, Chicago, IL, USA 13Celldex Therapeutics, Inc., Hampton, NJ, USA 14Dana-Farber Cancer Institute, Boston, MA, USA
Goldman has a strangle hold on this stock. Look at L2.
Interesting parallel with Nabriva CMO leaving shortly before critical trial data were expected. So we shouldn't read too much into the departure of Davis regarding the METRIC study results that will be coming out 2Q'18. Having said that, however, I think that Davis was still having difficulty nailing the dosing for Varli when he left.
Nabriva Therapeutics’ latest good news soothes concerns about chief medical officer’s departure
The company’s chief medical officer said she would be leaving mere weeks before important trial results for a key drug.
Should CLDX PR the 210th pfs event in the Metric Trial?
I say yes good info to know when it happens.
Personally, I'm starting to think, again, that BMS has a standing tentative agreement in place to either infuse Co. with major partnership funds or buy them outright. Who needs CMO if BO is tentative? According to that Cantor note below Co. isn't even looking to replace...hmm..?!
Good quality company right here folks. Just look at their past history of many successes. And other posters on this intelligent message board are claiming $40+ by next year. Better start mortgaging all you can for this one.....deal of a lifetime here.
Cantor put a $9 Price Target on this. Research report came out Tuesday. Highlights:
CLDX's Chief Medical Officer (CMO) Thomas Davis, M.D., is leaving the company to take on a role at an early-stage biotechnology company, effective 9/29/17. ■ We do not see implications for CLDX's clinical programs and continue to expect data from METRIC (1H18) and varlilumab (2018). ■ CLDX will not immediately replace Dr. Davis, but plans to maintain the current clinical science team. ■ CLDX will be appearing at the Cantor Global Healthcare conference September 25-27.
Wedge on the one month chart. Should be heading higher!
Hey Long - Re emerge study why are the hazard and p values so different between high expressors and triple negative high expressors with the smaller patient population i.e the trip negative showing better Haz ratio and p value with the same OS and PFS data?
Why would a top guy leave during a pivotal time? That's the question.
Look the *$%^ out below!!!!!!!!!!! Awesome volume today isnt it pumpers? Must be everyone buying for the "awesome" 4th Q metric BS news. Come on Marrucci and mismanagement team.....drop this pitch to where it belongs .0001. Ive tried to speak truth and warn of the scam that is CLDX. If you own it when it dilutes, R/S, or files BK dont say i didnt warn ya. This outfit has been a lying scam for 20 years.
News Out....Tom Davis has been named as the new CEO of Waste Management. Since he has got an awesome history of taking trash and manipulating it into something someone would buy!!!!!!!!!!!
NTEC + .45 8.95 NEW BUY REC FROM OPPENHEIMER FROM 10 - 15. NAILED IT AT 4.55 ANYONE ELSE GO FOR MY REC RIDE?
Everyone has got their hopes on Glembas metric trial leading to their first successful drug. Let me tell ya something....companies with a legitimate shot at approval don't trade for $2. The street and all big players know this is a dead end. Marrucci is just playing with the vulnerable small guy now baiting them to keep funding his retirement....actually he has been retired for 20 years.
When was the last time this co issued any positive information to shareholders? Its pretty evident things are not going good behind closed doors. When Rintega was in its prime they were issuing (false) positive PR's every other day to pump that scam. They arent even trying now....its that bad.
Bob Tidy is leaving Smelldex. The company cited streak marks as the cause of his resignation. "The company is one big streak mark, I don't get it". Mr Tidy took a job at Charmin company stating, "I wanted a postition closer to the action". Mr Tidy will SORELY missed.
ACRX's Dsuvia PDUFA date is October 12th, with the high analyst price target $13 or 300% upside potential... heads up...
smellydogdex bag holders really know how those folks in Puerto Rico feel, wiped out!!!Earthquakes, now another by the #$%$ meltdown plant, earthquake swarps at Yellowstone, North Korea and the Rocket Man, STD's anti biotic resistant on the rise, and what is smelldex working on.....nobody knows!
News out - Tom Davis, M.D. resigned as Celldex's Chief Medical Officer.